GRFS (Grifols) Quality Rank


GRFS Grifols SA GRFS
84 GF Score
Price $7.08
GF Value $8.92
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Grifols Quality Rank Related Terms

GRFS
84GF Score
Grifols SA GRFS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.08 is trading 20.7% below its estimated GF Value™ of $8.92. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Quality Rank:
  • GF Value™: $8.92 vs. price of $7.08 (20.7% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.08
Price
$8.92
GF Value